Moderna files data for EU authorization for its vaccine for adolescents

US biotech Moderna on June 7 filed data for an EU conditional marketing authorization for its COVID-19 vaccine for adolescents aged 12 to 18, Report informs referring to TASS.

It’s the second COVID-19 vaccine maker to apply for a license in children in the EU after BioNTech/Pfizer, whose mRNA vaccine was approved for adolescents on May 28.

In adolescents, two doses of Moderna’s mRNA vaccine were shown to be 100 percent effective at preventing illness from COVID-19 in a 2,500-participant trial. In addition, it was shown to be 93 percent effective at preventing illness, including milder cases, 14 days after the first dose in a 3,732-person trial.

At the moment, the EU has approved four vaccines: the development of the consortium BioNTech and Pfizer, a drug from Moderna, a vaccine from the British-Swedish company AstraZeneca and a drug from Johnson & Johnson. In addition, the vaccine of China's Sinopharm and Russia's Sputnik are available in Hungary.

On March 4, the European Medicines Agency announced the start of the sequential examination procedure for Sputnik V as part of the process of its registration in the EU. However, the timing of the completion of the trials is still unclear.